MICHAEL HACKMAN: Open Payments
NPI 1013150945 · HUNTINGTON, WV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$659 in 36 payments from 8 companies in 2025. Trend: 2023 $9,390 · 2024 $474 · 2025 $659
Food & beverage: $659
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $196 |
| Otsuka America Pharmaceutical, Inc. | 8 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Alkermes, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Novo Nordisk Inc | 1 | $19 |
Products named: VRAYLAR, REXULTI, TRINTELLIX, Auvelity, CAPLYTA, VIVITROL, ARISTADA, FANAPT.
Industry payments across WV — which companies pay providers there.
